Vanderbilt University Spasticity Management Program Evaluation Plan
Primary Purpose
Spasticity
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Botulinum Toxin Type A
Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
Sponsored by
About this trial
This is an interventional treatment trial for Spasticity focused on measuring Spasticity, Developmental Disabilities, Intrathecal baclofen (ITB), Botulinum Toxin Type A (Botox)
Eligibility Criteria
Inclusion Criteria: Adult with spasticity residing at Clover Bottom Developmental Center in Nashville, Tennessee. Spasticity must interfere with daily functioning. Care team must be able to identify at least one treatment goal for the potential participant. Exclusion Criteria: Family or guardian is unwilling to provide written informed consent. Spasticity does not interfere with patient's day-to-day care. Staff who provide daily care are unable to identify a clear treatment goal.
Sites / Locations
- Vanderbilt University Medical Center
Outcomes
Primary Outcome Measures
Total time (in seconds) spent by caregivers to complete a defined care area task at one year followup.
Categorical rating by blinded, independent reviewer of baseline and one-year care area task videos.
Secondary Outcome Measures
Range of motion score for each care area goal, assigned by physical therapist and compared at baseline vs. one-year followup.
Differences in the number of hospital admissions 12 months pre- and 12 months post-program.
Differences in costs associated with caregiving 12 months pre- and 12 months post-treatment.
Difference in Physician's global assessment of spasticity at baseline and one-year followup.
Full Information
NCT ID
NCT00179114
First Posted
September 13, 2005
Last Updated
August 17, 2007
Sponsor
Vanderbilt University
Collaborators
Allergan, Medtronic
1. Study Identification
Unique Protocol Identification Number
NCT00179114
Brief Title
Vanderbilt University Spasticity Management Program Evaluation Plan
Official Title
Vanderbilt University Spasticity Management Program Evaluation Plan
Study Type
Interventional
2. Study Status
Record Verification Date
August 2007
Overall Recruitment Status
Completed
Study Start Date
August 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Vanderbilt University
Collaborators
Allergan, Medtronic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
People with severe developmental disabilities frequently have comorbidities that make providing care to them more difficult. Spasticity is one such comorbidity. It produces increased muscle tone that can cause stiffness in joints and bodily contortions that can interfere with all of the major types of care provided to participants. Typically, care areas include splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in other functional activities. Moreover, persons with spasticity often experience pain.
Typically, spasticity is managed by health care providers using a combination of the following therapies:
Physical / occupational therapy (PT / OT)
Oral medication
Botox injections
Intrathecal baclofen administered by the Medtronic SyncroMed pump (ITB)
Orthopedic / neurological surgery
Detailed Description
As individuals are identified as appropriate participants for the Program and consent is obtained, the care team for each person, consisting of both medical and caregiver staff, will define up to three specific care area goals and related tasks for treatment. A comprehensive spasticity management program will then be developed for the individual. Clinical and outcome assessments at baseline and at follow-up will include measures of range of motion, global spasticity according to a modified Ashworth scale, and the time and number of staff required for the task. In addition, video will be obtained of caregivers performing each participant's care area tasks at baseline and follow-up to allow an independent external reviewer to judge task difficulty. Treatment will be provided as outlined by the spasticity management plan. Follow-up evaluations will be conducted when the participant is at least one year from their initial Botulinum injection, or are one year post-implant for ITB participants. When the participant is exited from the study, Survey Physician will be asked to rate the overall impact of the Program on each of the individual's care area tasks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spasticity
Keywords
Spasticity, Developmental Disabilities, Intrathecal baclofen (ITB), Botulinum Toxin Type A (Botox)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A
Intervention Type
Drug
Intervention Name(s)
Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
Primary Outcome Measure Information:
Title
Total time (in seconds) spent by caregivers to complete a defined care area task at one year followup.
Title
Categorical rating by blinded, independent reviewer of baseline and one-year care area task videos.
Secondary Outcome Measure Information:
Title
Range of motion score for each care area goal, assigned by physical therapist and compared at baseline vs. one-year followup.
Title
Differences in the number of hospital admissions 12 months pre- and 12 months post-program.
Title
Differences in costs associated with caregiving 12 months pre- and 12 months post-treatment.
Title
Difference in Physician's global assessment of spasticity at baseline and one-year followup.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult with spasticity residing at Clover Bottom Developmental Center in Nashville, Tennessee.
Spasticity must interfere with daily functioning.
Care team must be able to identify at least one treatment goal for the potential participant.
Exclusion Criteria:
Family or guardian is unwilling to provide written informed consent.
Spasticity does not interfere with patient's day-to-day care.
Staff who provide daily care are unable to identify a clear treatment goal.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Charles, MD
Organizational Affiliation
Vanderbilt University Department of Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Vanderbilt University Spasticity Management Program Evaluation Plan
We'll reach out to this number within 24 hrs